A recent EPO Board of Appeal (BoA) decision (T 1553/22) considered the patentability of human-animal chimeras (organisms or tissues that…
Read More
#MedicalSector
Filter By
2023 Patent Landscape Report: COVID-19-related vaccines and therapeutics
Since the start of the COVID-19 pandemic there have been remarkable research and innovation efforts to fight the SARS-COV-2 virus….
Read More
Unravelling the mysteries of motor neurone disease
Motor Neurone Disease (MND) is a debilitating neurodegenerative disease that affects the brain and spinal cord, leading to the death…
Read More
Lecanemab: could the drug with modest benefits make a big difference to Alzheimer’s patients?
Currently more than 55 million people live with dementia worldwide, with the number of people living with the disease expected to triple…
Read More
Protecting AI diagnostics – two bites at the AIpple?
The use of AI has revolutionised the speed and accuracy of diagnosis for a host of conditions including breast cancer,…
Read More
Data versus time in clinical trials: attaining the perfect balance
Clinical trials are an expensive and risky business. The investment of time, resources and costs grows with progression through the…
Read More
The verdict is in: it’s a yes from the FDA for the controversial Alzheimer’s drug, after a tricky year for Biogen
The pharmaceutical industry has eagerly awaited the decision from the US Food and Drug Administration (FDA) on the first new…
Read More
Keeping in line: intraoperative surgical guidance innovation
Surgery is, by its very nature, an invasive procedure. It can be transformative to the quality of life of those…
Read More
Why 3D technology gives hope to complex hip replacement cases
With so many of 2020’s headlines focussed on Covid and Brexit we can be forgiven for letting an important anniversary…
Read More